Drugs / CJC-1134-PC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01514149 | Sep 2011 → May 2012 | type 2 diabetes mellitus | ConjuChem | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00674466 | Mar → Nov 2008 | type 2 diabetes mellitus | ConjuChem | Completed | No outcome recorded |
| Phase 2 | NCT00638716 | Feb → Nov 2008 | type 2 diabetes mellitus | ConjuChem | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07057271 | May 2021 → Feb 2023 | type 2 diabetes mellitus | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07058545 | Apr 2021 → Feb 2023 | type 2 diabetes mellitus | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2009-06-08 | ConjuChem | Results ConjuChem Reports Data on PC-DAC(TM):Exendin-4 and PC-Insulin at 2009 American Diabetes Association Meeting conjuchem.com ↗
The first poster detailed previously disclosed results of two randomized, double-blind, placebo controlled phase II trials of PC-DAC(TM):Exendin-4, demonstrating that this long-lasting GLP-1 receptor agonist can significantly and safely reduce HbA1c and body weight. |
| 2007-06-19 | ConjuChem | Results ConjuChem Biotechnologies Reports PC-DAC(TM):Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting conjuchem.com ↗
All three treatment groups experienced reductions in fasting plasma glucose that were statistically significant versus baseline (p less than 0.005) and versus placebo (p less than 0.03) over the 5-week treatment period. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CJC-1134-PC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07057271 ↗ |
| Route | Subcutaneous | “CJC-1134-PC administered weekly by subcutaneous injection” NCT01514149 ↗ |